

September 24, 2026

BrightPath Presents Preclinical Data and Phase 1 Trial Design of iPSC-Derived BCMA CAR-iNKT Cell Therapy (BP2202) at IMS 2026

TOKYO, Japan, September 24, 2026/ — BrightPath Biotherapeutics Co., Ltd. (TSE Growth: 4594), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, today announced that the Company presented preclinical data and the Phase 1 clinical trial design for BP2202, an allogeneic, iPSC-derived BCMA CAR-iNKT cell therapy, at the 23rd International Myeloma Society Annual Meeting (“IMS 2026”), being held in Glasgow, Scotland, United Kingdom, from September 23 to 26, 2026. [The poster](#) was presented on September 23, 2026 (local time) and is now available on the Company’s website.

BP2202 is a BCMA-targeted CAR-iNKT cell therapy for multiple myeloma. BrightPath has established a technology to manufacture invariant natural killer T (iNKT) cells, which exert multifaceted antitumor activity, from iPSCs in a homogeneous and scalable manner. Following clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), BrightPath is currently activating clinical trial sites for the Phase 1 clinical trial of BP2202 in the United States. At IMS 2026, BrightPath reported preclinical data for BP2202 together with the design of this Phase 1 clinical trial.

IMS 2026 is one of the world’s leading scientific conferences in multiple myeloma, bringing together leading clinicians and researchers in the field, including prospective principal investigators at the clinical sites being activated for the trial.

[Key Highlights]

Preclinical Data

- BP2202 demonstrated tumor growth inhibition in a multiple myeloma xenograft mouse model.
- A comprehensive genomic safety assessment of the master iPSC bank, the starting material for manufacturing the investigational product (BCMA CAR-iNKT cells), including karyotyping, optical genome mapping, whole-genome sequencing and off-target analysis, confirmed chromosomal integrity, with no structural abnormalities of concern or notable off-target editing detected.
- The manufacturing process was shown to be highly reproducible, including consistent CAR expression.

Phase 1 Clinical Trial Design

- The trial is designed for patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy.

- The open-label, multicenter trial consists of a dose-escalation part evaluating three dose levels (Part A), followed by a dose-expansion part at the recommended dose (Part B).
- Following lymphodepletion, patients will receive three doses of BP2202 at the same dose level on Day 0, Day 7 and Day 14.

[Presentation Details]

Abstract Number: PA-058

Title: BP2202: An Off-the-Shelf iPSC-Derived BCMA-Targeted Cellular Therapy for Multiple Myeloma

Meeting Dates: September 23–26, 2026

Presentation: Poster, September 23, 2026, 12:00 p.m. BST (8:00 p.m. JST)

About BP2202:

BP2202 is an allogeneic, off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor targeting B cell maturation antigen (BCMA). By combining an iPSC-derived manufacturing platform with invariant natural killer T (iNKT) cells, BP2202 is designed to provide a readily available treatment option for patients with multiple myeloma. BP2202 is currently being evaluated in Phase 1 clinical development in the United States.

About BrightPath Biotherapeutics:

BrightPath (Tokyo Stock Exchange Growth: 4594) is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

Forward-Looking Statements:

This press release contains forward-looking statements concerning the development of BP2202, including the design and conduct of clinical trials and the potential therapeutic benefits of the product candidate. These statements are based on management's current assumptions and are subject to risks and uncertainties inherent in preclinical and clinical development, regulatory review, manufacturing, competition and financing. Actual results may differ materially. BrightPath undertakes no obligation to update these statements except as required by law.

Investor and Media Contact:

Administration Department,
BrightPath Biotherapeutics Co., Ltd.

E-mail: irpr@brightpathbio.com

<https://www.brightpathbio.com/English/>